tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2012-2-105-109tumors-123Research ArticleОБЗОРЫ И АНАЛИТИКАREVIEWS AND ANALYSISПЕРСОНАЛИЗИРОВАННАЯ ТЕРАПИЯ В ОНКОЛОГИИ: НАСТОЯЩЕЕ И БУДУЩЕЕФедянинМ. Ю.Отделение клинической фармакологии и химиотерапии РОНЦ им. Н.Н. Блохина РАМН, МоскваRussian Federation20122205201522105109Copyright © Федянин М.Ю., 20152015Федянин М.Ю.Федянин М.Ю.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/123
.
ReferencesK.N.Mendes, D. Nicorici, D. Cogdell et al. Analysis of signaling pathways in 90 cancer cell lines by protein lysate array. J. Proteome Res., 2007, 6 (7), pp 2753–2767.K.N.Mendes, D. Nicorici, D. Cogdell et al. Analysis of signaling pathways in 90 cancer cell lines by protein lysate array. J. Proteome Res., 2007, 6 (7), pp 2753–2767.Y.J. Kim, Y.S. Ha, S.K. Kim et al. Gene signatures for the prediction of response to bacillus Calmette-Guérin immunotherapy in primary pT1 bladder cancers. Clin Cancer Res 2010;16:2131-2137.Y.J. Kim, Y.S. Ha, S.K. Kim et al. Gene signatures for the prediction of response to bacillus Calmette-Guérin immunotherapy in primary pT1 bladder cancers. Clin Cancer Res 2010;16:2131-2137.M.Gerlinger, . A.J. Rowan, S. Horswell et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.M.Gerlinger, . A.J. Rowan, S. Horswell et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.Brannon AR, Reddy A, Seiler M, et al. Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Genes Cancer 2010;1:152-63.Brannon AR, Reddy A, Seiler M, et al. Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Genes Cancer 2010;1:152-63.L.V. Sequist, B. A. Waltman, D. Dias-Santagata et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3, 75ra26 (2011).L.V. Sequist, B. A. Waltman, D. Dias-Santagata et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3, 75ra26 (2011).Jung-min Lee . Feasibility and safety of sequential research-related tumor core biopsies in clinical trials with anti-angiogenic and targeted therapies. J Clin Oncol 30:5s, 2012 (suppl; abstr 2545).Jung-min Lee . Feasibility and safety of sequential research-related tumor core biopsies in clinical trials with anti-angiogenic and targeted therapies. J Clin Oncol 30:5s, 2012 (suppl; abstr 2545).Philippe Bedard. A phase lb, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors. J Clin Oncol 30:5s, 2012 (suppl; abstr 3003).Philippe Bedard. A phase lb, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors. J Clin Oncol 30:5s, 2012 (suppl; abstr 3003).Qian CN, Min HQ, Lin HL, et al. Primary study in experimental antiangiogenic therapy of nasopharyngeal carcinoma with AGM-1470 (TNP-470). J Laryngol Otol 1998;112:849-53.Qian CN, Min HQ, Lin HL, et al. Primary study in experimental antiangiogenic therapy of nasopharyngeal carcinoma with AGM-1470 (TNP-470). J Laryngol Otol 1998;112:849-53.Qian CN, Min HQ, Lin HL, et al. Anti-tumor effect of angiogenesis inhibitor TNP-470 on the human nasopharyngeal carcinoma cell line NPC/ HK1. Oncology 1999;57:36-41.Qian CN, Min HQ, Lin HL, et al. Anti-tumor effect of angiogenesis inhibitor TNP-470 on the human nasopharyngeal carcinoma cell line NPC/ HK1. Oncology 1999;57:36-41.Hui EP, Ma BB, King AD, et al. Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation. Ann Oncol 2011;22:1280-7.Hui EP, Ma BB, King AD, et al. Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation. Ann Oncol 2011;22:1280-7.Houk B.E., Bello C.L., Michaelson M.D. et al. A population pharmacokinetic/pharmaco-dynamic (PK/PD) analysis of exposure–response for sunitinib in metastatic renal cell carcinoma (mRCC). Presented at the 14th European Cancer Conference, 23–27. Barcelona: Spain September 2007.Houk B.E., Bello C.L., Michaelson M.D. et al. A population pharmacokinetic/pharmaco-dynamic (PK/PD) analysis of exposure–response for sunitinib in metastatic renal cell carcinoma (mRCC). Presented at the 14th European Cancer Conference, 23–27. Barcelona: Spain September 2007.Demetri G.D., Casale P.G., Bello C. et al. A population pharmacokinetic/pharmaco-dynamic (PK/PD) meta-analysis of sunitinib in patients with gastrointestinal stromal tumour. Presented at the 19th International Congress on Anti-Cancer Treatment, 5–8. Paris, France February 2008.Demetri G.D., Casale P.G., Bello C. et al. A population pharmacokinetic/pharmaco-dynamic (PK/PD) meta-analysis of sunitinib in patients with gastrointestinal stromal tumour. Presented at the 19th International Congress on Anti-Cancer Treatment, 5–8. Paris, France February 2008.G.R. Blumenschein. Final results of a phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN). J Clin Oncol 30:5s, 2012 (suppl; abstr 5592).G.R. Blumenschein. Final results of a phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN). J Clin Oncol 30:5s, 2012 (suppl; abstr 5592).C. Xue, S. Yat-sen. A phase II study of sorafenib in combination with cisplatin and 5-fluorouracil in the treatment of recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 30:5s, 2012 (suppl; abstr 5538).C. Xue, S. Yat-sen. A phase II study of sorafenib in combination with cisplatin and 5-fluorouracil in the treatment of recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 30:5s, 2012 (suppl; abstr 5538).Kutter C., Svoboda P. Meeting report: miRNA, siRNA, piRNA. Knowns of the unknown. RNA Biology 5:4, 181-188; October/November/December 2008.Kutter C., Svoboda P. Meeting report: miRNA, siRNA, piRNA. Knowns of the unknown. RNA Biology 5:4, 181-188; October/November/December 2008.J.S. Duncan, M.C. Whittle, K.Nakamura et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149, 307–321, April 13, 2012J.S. Duncan, M.C. Whittle, K.Nakamura et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149, 307–321, April 13, 2012Artale S, Sartore-Bianchi A, Veronese SM, et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. Journal of Clinical Oncology 2008;26(25):4217–9.Artale S, Sartore-Bianchi A, Veronese SM, et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. Journal of Clinical Oncology 2008;26(25):4217–9.R.E. Kast. Epithelial ovarian cancer: A feasible plan for adjunctive treatment using simultaneous acyclovir, ambrisentan, captopril, disulfiram, fluvoxamineaugmented ramelteon, atibant, imiquimod peritoneal lavage, and plerixafor. Journal of Cancer Therepeutics & Research 2012.R.E. Kast. Epithelial ovarian cancer: A feasible plan for adjunctive treatment using simultaneous acyclovir, ambrisentan, captopril, disulfiram, fluvoxamineaugmented ramelteon, atibant, imiquimod peritoneal lavage, and plerixafor. Journal of Cancer Therepeutics & Research 2012.
The authors declare that there are no conflicts of interest present.